Ardelyx amends license deal with Kyowa Kirin for tenapanor
Initially executed in 2017, the agreement grants exclusive rights to Kyowa Kirin for the development and commercialisation of Ardelyx’s tenapanor to treat cardiorenal diseases including hyperphosphatemia in Japan.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.